Paul Nyandoto

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

Seppo Pyrhönen, Tapio Kuitunen, Paul Nyandoto et al. · British Journal of Cancer · 1995 · 794 citations · Full text

Surgical Oncology, Oncology, Gastrointestinal Oncology +6

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Pirkko‐Liisa Kellokumpu‐Lehtinen, Ulrika Harmenberg, Timo Joensuu et al. · The Lancet Oncology · 2013 · 205 citations

Urology, Oncology, Genitourinary Cancer +5

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Heikki Joensuu, Judith Fraser, Hans Wildiers et al. · JAMA Oncology · 2018 · 145 citations · Full text

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · Journal of Clinical Oncology · 2011 · 116 citations · Full text

Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study

Pia Österlund, Tapio K. Salminen, Leena-Maija Soveri et al. · The Lancet Regional Health - Europe · 2021 · 104 citations · Full text